Aztreonam now available by inhalation for P. aeruginosa in cystic fibrosis

Published: 2010-03-10

The FDA has granted marketing authorisation for Cayston (aztreonam for inhalation solution) as a treatment for adult cystic fibrosis patients with chronic airway infection caused by Pseudomonas aeruginosa. Marketing authorisations have also been granted in Australia, Canada and the EU.

Cayston is administered at a dose of 75 mg three times daily over a 28-day period and is delivered via a portable, specially designed nebuliser.

Cayston’s safety and efficacy have not been established in paediatric patients below the age of seven, patients with forced expiratory volume in one second (FEV1) of less than 25% or greater than 75% predicted, or patients colonized with Burkholderia cepacia.

www.gilead.com